AntifungalsMulti-drug resistance, and transient rash following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1945卷 / 1期

关键词：

D O I：

10.1007/s40278-023-34147-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：66 / 66

相关论文

共 50 条

[21] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[22] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[23] DexamethasoneHyperglycaemia following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 173 - 173
[24] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[25] FavipiravirNephrotoxicity following off-label use: case report
Reactions Weekly, 2022, 1929 (1) : 283 - 283
[26] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[27] FavipiravirDisseminated erythematous drug eruption following an off-label use: case report
Reactions Weekly, 2023, 1982 (1) : 188 - 188
[28] Multiple drugsLack of drug effect following off-label use: case report
Reactions Weekly, 2021, 1856 (1) : 289 - 289
[29] KetamineVarious toxicities following overdose of off-label drug use: case report
Reactions Weekly, 2023, 1976 (1) : 188 - 188
[30] RisdiplamPneumonia following off-label use: case report
Reactions Weekly, 2023, 1950 (1) : 348 - 348

← 1 2 3 4 5 →